

ARRAY BIOPHARMA INC  
Form 8-K  
May 03, 2016

---

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): May 3, 2016**

**Array BioPharma Inc.**

*(Exact name of registrant as specified in its charter)*

**Delaware**

*(State or other jurisdiction of incorporation)*

**001-16633**

*(Commission File Number)*

**84-1460811**

*(I.R.S. Employer Identification No.)*

**3200 Walnut Street, Boulder, Colorado 80301**

*(Address of principal executive offices, including Zip Code)*

**(303) 381-6600**

*(Registrant's telephone number, including area code)*

Edgar Filing: ARRAY BIOPHARMA INC - Form 8-K

*(Former name or former address, if changed since last report)*

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

In this report, “Array BioPharma,” “Array,” “we,” “us” and “our” refer to Array BioPharma Inc., unless the context otherwise provides.

**Item 2.02 Results of Operations and Financial Condition.**

On May 3, 2016, Array BioPharma Inc. issued a press release reporting results for the third quarter of fiscal year ending June 30, 2016, the full text of which is attached hereto as Exhibit 99.1. The information in Item 2.02 of this Form 8-K and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 9.01 Financial Statements and Exhibits.**

**(d) Exhibits**

**Exhibit No. Description**

99.1 Press release dated May 3, 2016 entitled “Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2016”

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 3, 2016 Array BioPharma Inc.

By: /s/ DAVID HORIN  
David Horin  
Interim Chief Financial Officer

**EXHIBIT INDEX**

**Exhibit No. Description**

99.1	Press release dated May 3, 2016 entitled “Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2016”
------	---